Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVax-L and Nivolumab in Recurrent Glioblastoma
NCT03014804Phase 2Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of DCVax-L, nivolumab in glioblastoma (GBM), sponsored by UCLA Jonsson Comprehensive Cancer Center. Planned start Dec 2019; status: withdrawn.
02
Drugs
DCVax-Lnivolumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03014804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014804.